Eli Lilly acquires SiteOne Therapeutics for up to $1B, signaling potential uptick in Big Pharma deals and focus on non-opioid ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

If approved by regulators, the acquisition would give Lilly strategic access to STC-004, an experimental non-opioid pain medication that is part of a class of drugs called Nav1.8 inhibitors.

SiteOne Therapeutics is developing a non-opioid therapy that targets sodium ion channels in the human body to treat pain and ...

Shares of Ozempic and Wegovy manufacturer Novo Nordisk (NYSE: NVO) reacted positively to the news and are up 4.9% as of 10:20 a.m. ET. Where to invest $1,000 right now? Our analyst team just revealed ...

The payments have raised concerns that doctors could be influenced to favour specific drugs or prescribe them over talking ...

Tariffs on pharmaceutical imports could hurt Lilly, especially with its dependence on products made in Ireland. The president ...

They worry tariffs, aimed at bringing drug production to the United States, could instead drive companies out of business ...

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

Tirzepatide, the newest weight loss drug in India, is transforming the wellness market with its hormone-mimicking effects.

Online prescriptions – for everything from weight loss to medicinal cannabis – is now a big business backed by Woolworths and ...

Detailed price information for JP Morgan Chase & Company (JPM-N) from The Globe and Mail including charting and trades.